Atomoxetine attenuates dextroamphetamine effects in humans

American Journal of Drug and Alcohol Abuse

Volumn 35, Issue 6, 2009, Pages 412-416

  Sofuoglu, Mehmet ^a   Poling, James ^a   Hill, Kevin ^b,c   Kosten, Thomas ^d  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c MCLEAN HOSPITAL   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Atomoxetine; Dextroamphetamine; Norepinephrine

Indexed keywords

ATOMOXETINE; DEXAMPHETAMINE; HYDROCORTISONE; PLACEBO;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; DRUG RESPONSE; FEMALE; HEART RATE; HORMONE RESPONSE; HUMAN; HUMAN EXPERIMENT; HYDROCORTISONE BLOOD LEVEL; MALE; NORADRENERGIC SYSTEM; NORMAL HUMAN; SELF REPORT; SINGLE DRUG DOSE; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION;

ADRENERGIC UPTAKE INHIBITORS; ADULT; AFFECT; BLOOD PRESSURE; CENTRAL NERVOUS SYSTEM STIMULANTS; DEXTROAMPHETAMINE; DRUG INTERACTIONS; FEMALE; HEART RATE; HUMANS; HYDROCORTISONE; MALE; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; PROPYLAMINES;

EID: 73349124789     PISSN: 00952990     EISSN: 10979891     Source Type: Journal    
DOI: 10.3109/00952990903383961     Document Type: Article

References (20)

1. Florin SM, Kuczenski R, Segal DS. Regional extracellular norepinephrine responses to amphetamine and cocaine and effects of clonidine pretreatment. Brain Res 1994; 654 (1):53-62.
2. Kuczenski R, Segal DS. Effects of methylphenidate on extracellular dopamine, serotonin, and norepinephrine: comparison with amphetamine. J Neurochem 1997; 68 (5):2032-2037. (Pubitemid 27176139)
3. Brauer LH, De Wit H. High dose pimozide does not block amphetamineinduced euphoria in normal volunteers. Pharmacol Biochem Behav 1997; 56(2):265-272.
4. Rothman RB, BaumannMH, Dersch CM, RomeroDV, Rice KC, Carroll FI, Partilla JS. Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse 2001; 39(1):32-41.
5. Berridge CW, Devilbiss DM, Andrzejewski ME, Arnsten AF, Kelley AE, Schmeichel B, Hamilton C, Spencer RC. Methylphenidate preferentially increases catecholamine neurotransmission within the prefrontal cortex at low doses that enhance cognitive function. Biol Psychiatry 2006; 60(10):1111-1120.
6. Arnsten AF. Stimulants: Therapeutic actions in ADHD. Neuropsychopharmacology 2006; 31(11):2376-2383.
7. Simpson D, Plosker GL. Atomoxetine: a review of its use in adults with attention deficit hyperactivity disorder. Drugs 2004; 64(2): 205-222.
8. Bymaster FP, Katner JS, Nelson DL, Hemrick-Luecke SK, Threlkeld PG, Heiligenstein JH, Morin SM, Gehlert DR, Perry KW. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: A potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 2002; 27(5): 699-711.
9. Brauer LH, de Wit H. Subjective responses to d-amphetamine alone and after pimozide pretreatment in normal, healthy volunteers. Biol Psychiatry 1996; 39(1):26-32.
10. Fillmore MT, Rush CR, Marczinski CA. Effects of d-amphetamine on behavioral control in stimulant abusers: The role of prepotent response tendencies. Drug Alcohol Depend 2003; 71(2):143-152.
11. Seiden LS, Sabol KE, Ricaurte GA. Amphetamine: effects on catecholamine systems and behavior. Annu Rev Pharmacol Toxicol 1993; 33:639-677.
12. Grady TA, Broocks A, Canter SK, Pigott TA, Dubbert B, Hill JL, Murphy DL. Biological and behavioral responses to D-amphetamine, alone and in combinationwith the serotonin3 receptor antagonist ondansetron, in healthy volunteers. Psychiatry Res 1996; 64 (1):1-10.
13. Chamberlain SR, Muller U, Cleary S, Robbins TW, Sahakian BJ. Atomoxetine increases salivary cortisol in healthy volunteers. J Psychopharmacol 2007; 21(5):545-549.
14. Charmandari E, Tsigos C, Chrousos G. Endocrinology of the stress response. Annu Rev Physiol 2005; 67:259-284.
15. McNair D, Lorr M, Dropperman L.Manual for Profile of Mood States. San Diego, CA: Educational and Industrial Testing Services, 1971.
16. Stoops WW, Blackburn JW, Hudson DA, Hays LR, Rush CR. Safety, tolerability and subject-rated effects of acute intranasal cocaine administration during atomoxetine maintenance. Drug Alcohol Depend 2008; 92(1- 3):282-285.
17. Han DD, Gu HH. Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs. BMC Pharmacol 2006; 6:6.
18. Vanderschuren LJ, Beemster P, Schoffelmeer AN. On the role of noradrenaline in psychostimulant-induced psychomotor activity and sensitization. Psychopharmacology (Berl) 2003; 169(2):176-185.
19. Kelly CB, McAree S, Cooper SJ, StevensonM. The effects of reboxetine, a noradrenaline reuptake inhibitor, on the plasma noradrenaline response to a cold pressor test in healthy volunteers. J Psychopharmacol 2002; 16(4):333-336.
20. Szabo ST, Blier P. Effect of the selective noradrenergic reuptake inhibitor reboxetine on the firing activity of noradrenaline and serotonin neurons. Eur J Neurosci 2001; 13(11):2077-2087.